What diagnostic workup for systemic lupus erythematosus (SLE) can differentiate infection from a lupus flare?

Differentiating Infection from SLE Flare: Diagnostic Workup

Use C-reactive protein (CRP) >24 mg/L as the primary biomarker to identify infection in SLE patients, as it is the only independent risk factor for infection, while procalcitonin (PCT) >0.048 ng/mL helps identify lupus flares rather than infection 1.

Algorithmic Approach to Workup

Step 1: Initial Laboratory Assessment

CRP is your key discriminator:

• CRP >24 mg/L strongly suggests infection (odds ratio 2.896) 1
• CRP typically remains low or minimally elevated in lupus flares alone
• In infected-inactive SLE, CRP is significantly higher than noninfected-inactive disease 1

Important caveat: CRP elevation may be blunted in infected-active disease compared to infected-inactive disease, making interpretation more challenging when both conditions coexist 1.

Step 2: Add Procalcitonin for Flare Assessment

PCT helps identify lupus activity:

• PCT >0.048 ng/mL is an independent risk factor for SLE activity (OR 3.498), not infection 1
• PCT is significantly higher in infected-active versus infected-inactive groups 1
• PCT does not significantly differ between noninfected-active and noninfected-inactive groups 1

Step 3: Complete Blood Count with Differential

Neutrophil-to-lymphocyte ratio (NLR) provides additional discrimination:

• NLR >5.70 indicates infection with 75% sensitivity and 90% specificity (AUC 0.872) 2
• NLR is markedly elevated in SLE with infection (14.2 ± 15.4) versus SLE with flare alone (3.3 ± 2.2) 2
• Combining NLR >5.70 with CRP >1.28 mg/dL increases specificity to 98.3% 2

Platelet count assessment:

• Platelet count <150 × 10⁹/L is an independent risk factor for SLE activity (OR 4.391), not infection 1
• Platelet-to-lymphocyte ratio (PLR) is higher in infection (357.7 ± 350.1) versus flare (231.7 ± 152.9) 2

Step 4: Disease Activity Markers

Check lupus-specific markers to assess flare:

• Anti-dsDNA antibodies 3
• Complement levels (C3, C4)
• Disease activity scores (SLEDAI or similar)

These markers help confirm lupus activity but do not exclude concurrent infection 4, 5.

Practical Clinical Algorithm

1. Measure CRP and NLR first:

   • If CRP >24 mg/L AND NLR >5.70 → Strongly favor infection
   • If CRP <24 mg/L AND NLR <5.70 → Favor lupus flare

2. Add PCT and platelet count:

   • If PCT >0.048 ng/mL AND platelets <150 × 10⁹/L → Favor lupus flare (may coexist with infection)
   • If PCT low AND platelets normal → Less likely active lupus

3. Assess lupus activity markers:

   • Rising anti-dsDNA, falling complement → Supports flare
   • Stable serologies → Favors infection alone

4. Consider combined scoring:

   • Using multiple biomarkers together is superior to any single marker 1, 5
   • The logistic model combining CRP, PCT, and platelet count has significantly larger AUC than individual variables 1

Critical Pitfalls to Avoid

Do not rely on a single biomarker 5. The distinction between infection and flare is "extremely difficult" 5, and using only one marker is insufficient 5.

Recognize that both conditions can coexist. The infected-active group represents patients with concurrent infection and lupus flare, making interpretation more complex 1.

Consider disease duration: Longer disease course (>96 months) is actually protective against active flares (OR 0.169) 1, which may help contextualize your assessment.

Remember that immunosuppression affects susceptibility: Patients on glucocorticoids and immunosuppressive therapy have compromised immune systems, increasing infection risk 4, 6.